BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

983 related articles for article (PubMed ID: 9382736)

  • 1. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge.
    Menon JN; Bretscher PA
    Eur J Immunol; 1996 Jan; 26(1):243-9. PubMed ID: 8566074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines.
    Krishnan L; Guilbert LJ; Russell AS; Wegmann TG; Mosmann TR; Belosevic M
    J Immunol; 1996 Jan; 156(2):644-52. PubMed ID: 8543816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis.
    Scott P
    J Immunol; 1991 Nov; 147(9):3149-55. PubMed ID: 1833466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
    Li J; Nolan TJ; Farrell JP
    Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulator and effector functions of T-cell subsets in human Leishmania infections.
    Kemp M
    APMIS Suppl; 1997; 68():1-33. PubMed ID: 9063493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response.
    Mattner F; Magram J; Ferrante J; Launois P; Di Padova K; Behin R; Gately MK; Louis JA; Alber G
    Eur J Immunol; 1996 Jul; 26(7):1553-9. PubMed ID: 8766560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T; Anam K; Ali N
    Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis.
    Sjölander A; Baldwin TM; Curtis JM; Handman E
    J Immunol; 1998 Apr; 160(8):3949-57. PubMed ID: 9558102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
    Webb JR; Kaufmann D; Campos-Neto A; Reed SG
    J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice.
    Gabaglia CR; Pedersen B; Hitt M; Burdin N; Sercarz EE; Graham FL; Gauldie J; Braciak TA
    J Immunol; 1999 Jan; 162(2):753-60. PubMed ID: 9916695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early production of IL-4 and induction of Th2 responses in the lymph node originate from an MHC class I-independent CD4+NK1.1- T cell population.
    von der Weid T; Beebe AM; Roopenian DC; Coffman RL
    J Immunol; 1996 Nov; 157(10):4421-7. PubMed ID: 8906817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunopathology of American tegumentary leishmaniasis].
    Castés M; Tapia FJ
    Acta Cient Venez; 1998; 49(1):42-56. PubMed ID: 10205916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells.
    Sadick MD; Heinzel FP; Shigekane VM; Fisher WL; Locksley RM
    J Immunol; 1987 Aug; 139(4):1303-9. PubMed ID: 3112230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T helper 1 response against Leishmania major in pregnant C57BL/6 mice increases implantation failure and fetal resorptions. Correlation with increased IFN-gamma and TNF and reduced IL-10 production by placental cells.
    Krishnan L; Guilbert LJ; Wegmann TG; Belosevic M; Mosmann TR
    J Immunol; 1996 Jan; 156(2):653-62. PubMed ID: 8543817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
    Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
    J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a strategy of universally efficacious vaccination against pathogens uniquely susceptible to cell-mediated attack.
    Bretscher PA; Menon JN; Ogunremi O
    J Biotechnol; 1996 Jan; 44(1-3):1-4. PubMed ID: 8717379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.